Iron Gate Global Advisors LLC Sells 200 Shares of Novo Nordisk A/S (NYSE:NVO)

Iron Gate Global Advisors LLC reduced its position in Novo Nordisk A/S (NYSE:NVO) by 8.1% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 2,266 shares of the company’s stock after selling 200 shares during the period. Iron Gate Global Advisors LLC’s holdings in Novo Nordisk A/S were worth $270,000 at the end of the most recent reporting period.

A number of other large investors also recently modified their holdings of NVO. 1620 Investment Advisors Inc. purchased a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at about $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S in the second quarter worth $25,000. Gilliland Jeter Wealth Management LLC increased its stake in shares of Novo Nordisk A/S by 200.0% in the second quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after acquiring an additional 120 shares during the period. Daiwa Securities Group Inc. acquired a new stake in shares of Novo Nordisk A/S in the third quarter worth $28,000. Finally, Abound Wealth Management grew its position in Novo Nordisk A/S by 257.4% during the second quarter. Abound Wealth Management now owns 218 shares of the company’s stock valued at $31,000 after buying an additional 157 shares during the period. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Analyst Ratings Changes

Several analysts have recently issued reports on the stock. BMO Capital Markets dropped their target price on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. One equities research analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Novo Nordisk A/S presently has an average rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Trading Up 1.8 %

NVO opened at $108.70 on Tuesday. The firm has a market cap of $487.77 billion, a price-to-earnings ratio of 35.18, a price-to-earnings-growth ratio of 1.38 and a beta of 0.40. Novo Nordisk A/S has a 52 week low of $94.73 and a 52 week high of $148.15. The business’s 50 day moving average is $112.81 and its two-hundred day moving average is $127.92. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.